Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator
A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.
Also called NCT04504188
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 300 participants
- Sponsor
- Registry
-
NCT04504188
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Unknown status
Technical summary
Registry record NCT04504188. Allocation not applicable; no masking; primary purpose treatment. Start 2021-03-08 (actual); primary completion 2024-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator
- Acronym
- OPT-BB WOMEN
- Condition
- Cardiomyopathies
- Condition
- Heart Failure
- Intervention (Device)
- Heart Rate Monitor Enhanced Treatment Optimization
- Lead sponsor
- Zoll Medical Corporation
Record details
- Record id
cardio:ct-nct04504188- Content hash
56c56fb2ecd28842b1bf6c7554b4d4f7036a2895d0d9712af39d3edcc6285fcd